Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q4 FY2011 Earnings Presentation
17 slides from Jubilant Pharmova's earnings presentation, Mar 31, 2011
Slide 1: Financial Results Analysis Q4'11 and Full Year ending March 31, 2011
Financial Results Analysis y Q4’11 and Full Year ending March 31, 2011
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Financial Highlights
Financial Highlights • Net Sales at Rs. 890crore for Q4’11 and Rs. 3,433crore in FY11 • Revenue from Products at Rs 698crs grew 12% in Q4’11, Q4 11, at Rs 2,685crs in FY11, up 9% • Revenue from Services Business at Rs 192cr in Q4’11, at Rs 749crs for FY11, down 19% • EBITDA at Rs. 137crore in Q Q4’1
Slide 4: Profit and Loss Account
Profit and Loss Account Particulars (Rs Crs) Q4'FY10 Q4'FY11 FY10 FY11 Net Sales 902 890 3,386 3,433 Others 5 9 25 22 Total Income 907 899 3,411 3,455 Total Expenditure 688 762 2,601 2,888 Operating Profit Before Int., Dep. & Tax 219 137 810 567 Depreciation 32 33 124 180 Interest (Net) 34 32 150 10
Slide 5: Revenue Analysis – Business wise
Revenue Analysis – Business wise (Rs Crs) (%) (Rs Crs) (%) Q4'FY10 Q4'FY11 Variance FY10 FY11 Variance Life Science Ingredients 521 573 10% 2084 2233 7% Generics 101 125 24% 383 452 18% Life Science Products 622 698 12% 2,467 2,685 9% (Rs Crs) (%) (Rs Crs) (%) Q4'FY10 Q Q Q4'FY11 Variance FY10 FY11
Slide 6: Revenue Analysis – Detailed
Revenue Analysis – Detailed FY10 FY11 Growth Business (Rs Crs) (Rs crs) (%) Life Sciences Products 2467 2685 218 9% Life Science Ingredients 2,084 2,233 149 7% Proprietary Prod. & Excl. Synthesis 945 949 4 0% Nutritional Ingredients 197 192 (5) ‐3% Life Science Chemicals 659 755 96 15% Active Pharma
Slide 7: Highlights – Life Science Products
Highlights – Life Science Products Life Science Products Revenue at Rs 698cr in Q4’11, Rs 2,685cr in FY11 • In Q4’11, contributed 78% to Sales, grew 12% with volume growth of 13% • In FY11, contributed 78% to Sales, grew 9% with volume growth of 15% 1. Life Science Ingredients – Rs 573cr in Q4’11, R
Slide 8: Highlights – Life Science Products Generics
Highlights – Life Science Products 2 Generics 2. G i B Business i – Revenues R off Rs R 125cr 125 iin Q4’11 Q4’11, Rs R 452cr 452 in i FY11 • In Q4’11, contributed 14% to Total Revenue which grew 24%, volume growth 28% • In FY11, contributed 13% to Total Revenue with 18% growth, volume growth of 25%
Slide 9: Highlights – Life Science Services
Highlights – Life Science Services Life Science Services Business Revenues at Rs193cr in Q4, Rs 749cr in FY11 • In Q4 & FY11, contributed 22% share to Revenues with reduction of 31% and 19% respectively 1. CMO Services of Sterile and Non‐sterile • Contributed 15% to Q4 Q4’11 11 and FY11 revenue • Ex
Slide 10: Revenue Analysis – Geography wise
Revenue Analysis – Geography wise Q4’11 Geo‐Mix Rs Crs. FY11 Geo‐Mix Rs. Crore Rs Crs. International 1,264 , 37% 333 , 37% North International North America America 1,063 , 31% 2,370 , 69% 289 , 32% 602 , 68% Domestic 536 , 16% Europe 132 , 15% Europe Domestic 327 , 9% China 71 , 8% China 243 , 7% E
Slide 11: Operating Expenditure Analysis
Operating Expenditure Analysis Costs Quarterly Analysis Annual Analysis (Rs Crs) Q4’10 % of Sales Q4’11 % of Sales Change % FY10 % of Sales FY11 % of Sales Change % Material 396 44% 390 44% ‐1% 1,440 43% 1,543 45% 7% Manufacturing 70 8% 86 10% 22% 268 8% 294 9% 10% Staff 177 20% 183 21% 3% 709 21% 7
Slide 12: EBITDA Analysis
EBITDA Analysis Quarterly Analysis Year To Date Analysis EBITDA (Rs Crs) Q4’10 Q4’11 Variance FY10 FY11 Variance Products 188 137 (51) 728 600 (128) Services 48 20 (28) 146 35 (111) EBITDA 236 157 (79) 874 635 (239) Allocations 17 20 3 64 68 4 Margins (%) Q4’10 Q4’11 FY10 FY11 Products 30.3% 19.6% ‐
Slide 13: Debt Profile
Debt Profile Particulars In Rs Crs In USD Mn 31‐Dec‐10 31‐Mar‐11 31‐Dec‐10 31‐Mar‐11 Foreign Currency 760 847 170 190 Jubilant Standalone Rupee 588 1509 131 338 FCCB 635 634 142 142 Foreign Currency 970 868 217 195 Subsidiaries Rupee 26 26 6 6 Gross Debt 2,979 3,884 666 871 Cash & equivalents 98 1,0
Slide 14: Plans and Strategic Initiatives for Growth…
Plans and Strategic Initiatives for Growth… Strategy for growth in Sales is largely attributed to increased capacity utilisation, utilisation commissioning of new plants, innovation led new launches and expansion of market geographies Commissioning of new plants and expansion of existing plants
Slide 15: …Plans and Strategic Initiatives for Growth
…Plans and Strategic Initiatives for Growth Innovation led 55 New launches 26 launches in Solid Dosage Form and 19 in APIs; in therapeutic areas of CVS, CNS, Anti Infective, Anti Ulcerant and Anti Allergic 10 products d iin Proprietary P i P Products d & EExclusive l i SSynthesis h i Geograp
Slide 16: Outlook
Outlook In FY12, the Company is expected to post robust b growth h in sales l andd operating profits f to witness substantial improvement quarter on quarter Based on exchange rate assumptions of Rs44 Rs44.50 50 to US$ 1 15 15
Slide 17: For more information
For more information Visit us at www.jubl.com Contact us at nidhi_aggarwal@jubl.com Ph: h +91‐120 9 20 4361002 36 002 siddharth@cdr‐india.com Ph: +91‐22 6645 1209 16 16
Jubilant Life Sciences — Q4 FY2011 Earnings Presentation on 6ix